卡培他滨治疗蒽环类及紫杉类耐药的复发转移性乳腺癌的临床观察

目的:观察卡培他滨对蒽环类、紫杉类耐药的复发转移性乳腺癌的作用。方法:40例复发转移性乳腺癌患者,均经过蒽环类及紫杉类治疗后出现疾病进展。给予卡培他滨2510mg/(m2·d),分2次口服,连服2周,3周为1个周期。至少2个周期后评价疗效。结果:本组化疗均数为4个周期。CR1例,PR8例,SD23例,PD7例,有效率23.1%,疾病控制率(CR PR SD)为82.0%(32/39);TTP3.4个月;中位生存时间11.2个月。常见不良反应为手足综合征(70.0%)、皮肤色素沉着(60.0%)、恶心呕吐(52.5%)、腹泻(42.5%),2例出现3～4级严重腹泻而住院治疗。结论:卡培他滨对蒽环类、紫杉类耐药的复发转移性乳腺癌仍有一定的疗效,耐受性较好。

Clinical observation of capecitabine in the treatment of patients with anthracycline-and taxane-resistant metastatic breast cancer

Objective:To evaluate the response rate and adverse reactions of capecitabine in the treatment of patients with anthracycline- and taxane-pretreated metastatic breast cancer.Methods:Forty metastatic breast cancer patients failed to anthracyclines and taxanes were given 2 500mg/m2 in divided doses daily for 2 weeks every 3 weeks. Evaluations were performed after 2 cycles.Results:All patients completed on average four cycles. The overall response rate was 23.1%, including complete response 1 case(2.56%), partial response 8 cases(20.5%), stable disease 23 cases(59.0%), and progressive disease 7 cases(17.9%). The disease control rate (CR PR SD) was 82.0%. Median time to disease progression was 3.4 months, the median survival time was 11.2 months. The common treatment-related adverse events were hand-foot syndrome (70.0%), skin pigmentation (60.0%), nausea and vomiting (52.5%), and diarrhea (42.5%). However, two patients had severe diarrhea needed hospitalization.Conclusion:Capecitabine is active for the patients with anthracycline- and taxane-pretreated metastatic breast cancer with acceptable tolerance.